BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis

Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More